Previous 10 | Next 10 |
PALO ALTO, Calif. , March 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the fo...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most i...
Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...
PALO ALTO, Calif. , Feb. 27, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcomi...
Neoleukin Therapeutics (NASDAQ: NLTX ) initiated with Buy rating and $20 (82% upside) price target at Guggenheim. More news on: Xeris Pharmaceuticals, Inc., Neoleukin Therapeutics, Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...
Kodiak Sciences ( KOD +9% ) announces encouraging results from a Phase 1b clinical trial evaluating KSI-301, an anti-VEGF antibody biopolymer conjugate with a potential dosing interval of three months or longer, in patients with treatment-naïve wet age-related macular degeneration...
AbbVie (NYSE: ABBV ) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket. More news on: AbbVie Inc., Alkermes plc, BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Kodiak Sciences (NASDAQ: KOD ) has been on fire since September, gaining more than 400%. More news on: Kodiak Sciences Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
PALO ALTO, Calif. , Feb. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that a presentation of additional clinical study data...
Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform PR Newswire Tarcocimab clinical and non-clinical data high...